ERFURT,
Dear Shareholders,
The upcoming year will be transformational for AMP and the medical cannabis industry in
AMP's focus has always been to supply German patients with the highest quality cannabis products available. Our strength is having front-line relationships with the distributors of medical cannabis to pharmacies, the only point-of-sale for medical cannabis to German patients, which allows us to respond to market changes quickly.
In
These milestone announcements from the UN and the EU establish that cannabis has medical and wellness benefits for patients and significantly broadens its medical applications. This is a turning point where the education and knowledge will increase dramatically among the community of doctors, pharmacists, and other practitioners about the medical benefits of cannabis for their patients.
This year,
This year, AMP reached an important milestone when we generated our first sales in July from
We also received an AmRadV license, which allows us to import irradiated cannabis products from within and outside the EU, which have undergone microbial germ reduction from
To ensure the highest quality, cultivation, and manufacturing standards, we engaged the German pharmaceutical consulting company,
Now that we are fully licensed and have a variety of imported medical cannabis products for sale to national and specialized pharmaceutical distributors and large pharmacies that specialize in fulfilling medical cannabis prescriptions, we expect our sales to grow significantly next year. Our strategic relationship with CC Pharma, the German subsidiary of Aphria Inc. (NASDAQ: APHA), which has over 13,000 pharmacies in its network, will allow us to offer our products across
We started building a strong sales team with the objective to have national coverage to coincide with the launch of our medical and wellness brands. We have been actively recruiting salespeople who have a successful track record in pharmaceutical sales and specifically in medical cannabis. Our sales team is led by a seasoned national sales manager with extensive experience in the medical cannabis industry in Germany.
Building our AMP brand is a key part of our strategy to build high gross margins, where we source white-label medical cannabis products that meet our product specifications and high-quality manufacturing standards and brand under the AMP name.
The first products in our sales catalogue were high-THC flower, which is currently the most prescribed medicine by doctors and selling at a premium pricing. In
Beginning this year, we saw a growing demand for extracts as doctors become more familiar with how to prescribe the different medical cannabis products available and pharmacists on how to fulfill prescriptions. To meet this growing demand, we started selling Little Green Pharma's single-source extract from
We have had to delay qualifying our non-European suppliers due to international pandemic travel restrictions and we do not expect AMP will be able to qualify our foreign suppliers to export to
To further educating the medical community about the benefits of cannabis, AMP will be holding education seminars across
To encourage the general discussion about cannabis, AMP released its first two of six episodes round table discussions about medical cannabis in
We will begin reporting our financial results in Euro instead of Canadian dollars beginning in Q4, 2020, our first full quarter of sales. In addition, we have engaged
To improve trading liquidity in
Everyone at AMP wishes to thank our fellow shareholders for their support and loyalty. Next year will be a transformational year for AMP as our sales significantly grow from selling our extensive product line of medical cannabis products.
We wish you and your families a Merry Christmas and a happy, healthy, and prosperous New Year.
Best regards,
Dr.
About
AMP social media links:
- Twitter: https://twitter.com/AMP_Cannabis
- LinkedIn: www.linkedin.com/company/ampgermancannabisgroup
- Facebook: www.facebook.com/AMPGCG
- Instagram: www.instagram.com/ampgcg
- Podcast: http://ow.ly/EqBc50BJ4xw
Media Kit: https://www.amp-eu.com/media-kit
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
SOURCE
© Canada Newswire, source